Skip to content

Comparison of plasma concentrations of verapamil in healthy adults using simple suspension

Comparison of plasma concentrations of verapamil in healthy Japanese adult males - Investigation of the effects of simple suspension and grinding

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031210270
Enrollment
6
Registered
2021-08-24
Start date
2021-08-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none Healthy volunteer

Interventions

Three different dosing patterns will be compared within the same subject. The order of administration and method of administration will be uniform. Phase 1: One 40 mg tablets of verapamil hydrochlorid
Pharmacokinetics

Sponsors

Sambe Takehiko
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: (1) Age: between 20 and 40 years old at the time of obtaining consent. (2) Gender: male (3) BMI (Body Mass Index: kg/m^2) is between 18.5 and 28.5 (rounded to the first decimal place). (4) Those who have the capacity to give consent, comply with the rules and regulations during participation in the study, undergo the preliminary examination specified in the study protocol, and report subjective symptoms. (5) Those who are judged to be healthy and eligible to participate in this study by the physician in charge of the research at the preliminary examination specified in the research protocol.

Exclusion criteria

Exclusion criteria: (1) Subjects with clinically problematic ECG abnormalities that may affect the safety of this study. (2) Patients with a history of drug abuse/dependence, alcohol abuse/dependence, cardiac, hepatic, renal, pulmonary, ocular, or hematologic disease that may affect the evaluation and safety of this study (3) Those who are taking drugs (including dietary supplements) that may affect the evaluation and safety of this study. (4) Those with a history of drug allergy. (5) Those who have been participating in other clinical trials for less than 3 months. (6) Others who are judged by the investigator to be ineligible for this study.

Design outcomes

Primary

MeasureTime frame
Pharmacokinetic parameters of verapamil hydrochloride in plasma (AUC0-24, Cmax)

Secondary

MeasureTime frame
Pharmacokinetic parameters of verapamil hydrochloride in plasma (t1/2, tmax)

Contacts

Public ContactKakei Ryu

Showa University Clinical Research Institute for Clinical Pharmacology and Therapeutics

ryu-k@med.showa-u.ac.jp+81-3-3300-5247

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026